23
Nov
2026

Unimark Remedies Ltd (Shamrock Group)

Exhibitor at CPHI India 2026 stand 2M51
About Us

We are a USFDA and EUGMP approved facility manufacturing APIs with 25 DMFs, 12 CEPs. Our key products are Tigecycline, Lisinopril, Montelukast, Nitrofurantoin, Nalidixic Acid, Flecainide, Moxifloxacin and Carbapenems. Our facilities have been certified by the US FDA, MHRA, EDQM, COFEPRIS,TGA, WHO and other MOH. The management of the company has changed recently, the Shamrock Pharma Group now has 100% ownership.   We have upgraded the facilities to improve quality standards, making it a world class API facility with a combined capacity of 350 KL.

  • Country/Region:
    India
  • On CPHI since:
    2023
  • Certificates:
    3
  • Employees:
    250 - 499
Company types
Biopharmaceutical company
Manufacturer/Innovator
Primary activities
API Producer
Contact info
  • 83-E, Hansraj Pragji Bldg, Off Dr. E Moses rd, Worli,, Mumbai, India
Event information
CPHI India 2026
  • 23 Nov 2026 - 25 Nov 2026
  • IICC, Yashobhoomi, Dwarka, Delhi
  • Visit us at stand 2M51

Unimark Remedies Ltd Resources (1)